Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial.

Authors:
Li S; Guo L; Zhou P; Tang J; Wang Z and 3 more

Journal:
Eye Vis (Lond)

Publication Year: 2022

DOI:
10.1186/s40662-022-00316-z

PMCID:
PMC9714121

PMID:
36451252

Journal Information

Full Title: Eye Vis (Lond)

Abbreviation: Eye Vis (Lond)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThis study was approved by the Ethics Committee Review Board of Peking University People’s Hospital (2021PHB405-001). All patients provided written informed consent before surgery. All procedures adhered to the tenets of the Declaration of Helsinki. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

Evidence found in paper:

"Funding This study was funded by Capital Clinical Diagnosis and Treatment Technology Research and Demonstration Application Project of China (Grant No. Z191100006619029) and National Key R&D Program of China (Grant No. 2020YFC2008200)."

Evidence found in paper:

"Trial registration: Registered at ClinicalTrials.gov ( NCT05414149 )."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025